lobbying_activities: 1843771

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1843771	8bf8a1f1-237c-4134-b6c5-c08b6d353ca4	Q2	WINNING STRATEGIES WASHINGTON	50796	KALEO	2016	second_quarter	PHA	Pharmaceutical drug development, Reducing opiod overdose deaths and S. 707; H.R. 3680 provisions related to Nalaxone; S. 2256 provisions related to Nalaxone	HOUSE OF REPRESENTATIVES,SENATE	30000		0	0	2016-07-15T14:13:01.570000-04:00